## Edgar Filing: Sinha Vikas - Form 4

Sinha Vikas Form 4 April 04, 2011 FORM 4 Check this box if no longer subject to Section 16, Form 5 obligations may continue. See Instruction 1(b).											
(Print or Type I	Responses)										
Sinha Vikas Symbo ALEX			Symbol ALEXI	Issuer Name <b>and</b> Ticker or Trading nbol EXION PHARMACEUTICALS C [ALXN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (	, , , , ,				Director 10% Owner X_ Officer (give title Other (specify					
(Month/Day/Year)								( <b>F</b> )			
				endment, Date Original nth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li>Form filed by Mara than One Reporting</li> </ul>			
CHESHIRE, CT 06410 Form filed by More than One Reporting Person											
(City)	(State)	(Zip)	Tabl	e I - Non-I	Derivative	Securi	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Transaction Date 2A. Deemed onth/Day/Year) Execution Date, if any (Month/Day/Year)			4. Securit on(A) or Di (Instr. 3, 4	sposed 4 and 5 (A) or	of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$.0001 per share	04/01/2011			Code V M	Amount 10,000 (1)	(D) A	Price \$ 13.79	96,480	D		
Common Stock, par value \$.0001 per share	04/01/2011			S	10,000 (1)	D	\$ 100	86,480	D		

### Edgar Filing: Sinha Vikas - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 13.79	04/01/2011		S		10,000	12/21/2005	09/21/2015	Common Stock, par value \$.0001 per share	10,000

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
I Sector and the sector	Director	10% Owner	Officer	Other		
Sinha Vikas C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE, CT 06410			SVP & CFO			
Signatures						

/s/ Vikas Sinha

04/04/2011 Date

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The transaction reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1 (1) (c)(1) of the Securities Exchange Act.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.